Safety and effectiveness of mirabegron in male patients with overactive bladder with or without benign prostatic hyperplasia: A Japanese post‐marketing study
LUTS: Lower Urinary Tract Symptoms · 2021-01 · 13 (1) · 79-87
DOI: 10.1111/luts.12335 ↗Kurz gefasst
Fachartikel in der Zeitschrift LUTS: Lower Urinary Tract Symptoms, online erschienen am 05.08.2020. Verfasst von Satoru Takahashi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Nihon University, Tokyo, Japan. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Astellas Pharma Global Development; Astellas Pharma Inc..
Abstract (Originalsprache)
Objectives
The aim of this post hoc analysis from the Japanese mirabegron surveillance program was to investigate the safety and effectiveness of mirabegron in male patients with overactive bladder (OAB) symptoms with/without concomitant benign prostatic hyperplasia (BPH).
Methods
This 12‐week study included patients who were starting mirabegron treatment for the OAB symptoms of urinary urgency, daytime frequency, and urgency urinary incontinence. Patients were stratified according to BPH diagnosis, and patients with BPH were stratified into those who did/did not receive BPH‐specific treatment. Assessments included adverse drug reactions (ADRs), residual urine volume evaluations, and total Overactive Bladder Symptom Score (OABSS) and International Prostate Symptom Score‐Quality of Life (IPSS‐QoL) measurements.
Results
Of 4540 male patients, 3176 (70.0%) had been diagnosed with BPH. Mean age was slightly higher in patients with BPH (74.7 ± 8.41 years) versus patients without BPH (71.0 ± 12.13 years). Overall, 66/1364 (4.84%), 170/2588 (6.57%), and 35/569 (6.15%) patients without BPH, with BPH + treatment, and with BPH + no treatment, respectively, experienced ≥1 ADR. No patients without BPH and 21/3176 (0.66%) patients with BPH experienced a urinary retention ADR. No significant changes from baseline to week 12 in residual volume were noted. Mirabegron was judged to be an effective treatment for 990/1296 (76.4%) patients without BPH, 1935/2491 (77.7%) patients with BPH + treatment, and 421/538 (78.3%) patients with BPH + no treatment. Significant decreases in total OABSS and IPSS‐QoL were observed for all groups.
Conclusions
Mirabegron was a well‐tolerated and effective treatment for patients with OAB symptoms with or without BPH in this post‐marketing study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Nihon University, Tokyo, Japan.
- Medical Science, Medical Affairs, Astellas Pharma Inc., Tokyo, Japan.
- Japan-Asia Data Science, Development, Astellas Pharma Inc., Tokyo, Japan.
Förderung
- Astellas Pharma Global Development; Astellas Pharma Inc.
Zitieren
APA
Takahashi, S., Kato, D., Tabuchi, H., & Uno, S. (2021). Safety and effectiveness of mirabegron in male patients with overactive bladder with or without benign prostatic hyperplasia: A Japanese post‐marketing study. LUTS: Lower Urinary Tract Symptoms, 13(1), 79-87. https://doi.org/10.1111/luts.12335
Vancouver
Takahashi S, Kato D, Tabuchi H, Uno S. Safety and effectiveness of mirabegron in male patients with overactive bladder with or without benign prostatic hyperplasia: A Japanese post‐marketing study. LUTS: Lower Urinary Tract Symptoms. 2021;13(1):79-87. doi:10.1111/luts.12335
BibTeX
@article{Takahashi2021,
author = {Takahashi, Satoru and Kato, Daisuke and Tabuchi, Hiromi and Uno, Satoshi},
title = {Safety and effectiveness of mirabegron in male patients with overactive bladder with or without benign prostatic hyperplasia: A Japanese post‐marketing study},
journal = {LUTS: Lower Urinary Tract Symptoms},
year = {2021},
volume = {13},
number = {1},
pages = {79--87},
doi = {10.1111/luts.12335}
}
EUVIMED